Suchergebnisse - "Jerusalem, G"

PubPharm (226)

1

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant

enthalten in: Breast cancer research : BCR | 2023

von Neven, P. | Fasching, P. | Chia, S. | +15

2

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

enthalten in: Breast cancer research | 2023

von Neven, P. | Fasching, P. | Chia, S. | +15

3

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

enthalten in: Breast cancer research | 2023

von Neven, P. | Fasching, P. | Chia, S. | +15

4

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

enthalten in: The New England journal of medicine | 2023

von Partridge, A. | Niman, S. | Ruggeri, M. | +138

CommentIn: Cancer Discov. 2023 Jul 7;13(7):1504-1505. - PMID 37199496

5

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial

enthalten in: ESMO open | 2023

von de Azambuja, E. | Agostinetto, E. | Procter, M. | +19

6

CAR-T cells therapy in solid tumors : where are we now ?

enthalten in: Revue medicale de Liege | 2022

von Troisfontaine, F. | Denis, C. | Servais, S. | +2

7

Recurrent or primary metastatic cervical cancer : current and future treatments

enthalten in: ESMO open | 2022

von Gennigens, C. | Jerusalem, G. | Lapaille, L. | +4

8

Inflammation and cancer : a complex two-way relationship

enthalten in: Revue medicale de Liege | 2022

von Scheen, A. | Noël, A. | Delvenne, P. | +1

9

Continuous versus intermittent extended adjuvant letrozole for breast cancer : final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Jerusalem, G. | Farah, S. | Courtois, A. | +30

10

Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial : updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Slamon, D. | Neven, P. | Chia, S. | +17

ErratumFor: Ann Oncol. 2021 Aug;32(8):1015-1024. - PMID 34102253

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[23]